Annexin Pharmaceuticals AB (FRA:Q910) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 05, 2026)


FRA:Q910 Annexin Pharmaceuticals AB FRA:Q910
13 GF Score
Price €1.16
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Annexin Pharmaceuticals AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:Q910 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexin Pharmaceuticals AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's Margin of Safety % (DCF Earnings Based) falls into.


FRA:Q910
13GF Score
Annexin Pharmaceuticals AB FRA:Q910
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Business Description

Other Exchanges ANNX:Sweden
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
13GF Score

Get the complete analysis for FRA:Q910

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.16
Price